Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy NeoGenomics stock in Canada
Own NeoGenomics shares in just a few minutes.
NeoGenomics, Inc (NEO) is a leading diagnostics & research business based in the US. It opened the day at $47.11 after a previous close of $45.93. During the day the price has varied from a low of $46.89 to a high of $48.46. The latest price was $47.9472 (25 minute delay). NeoGenomics is listed on the NASDAQ and employs 1,700 staff. All prices are listed in US Dollars.
How to buy shares in NeoGenomics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: NEO in this case.
- Research NeoGenomics shares. The platform should provide the latest information available.
- Buy your NeoGenomics shares. It's that simple.
What's in this guide?
- Can I buy shares in NeoGenomics?
- NeoGenomics shares summary
- Compare share dealing platforms
- Is NeoGenomics stock a buy or sell?
- NeoGenomics performance over time
- Can I short NeoGenomics shares?
- Are NeoGenomics shares over-valued?
- NeoGenomics's financials
- How volatile are NeoGenomics shares?
- Does NeoGenomics pay a dividend?
- Have NeoGenomics shares ever split?
- Other common questions
NeoGenomics share priceUse our graph to track the performance of NEO stocks over time.
NeoGenomics shares at a glance
|52-week range||$25.19 - $61.57|
|50-day moving average||$47.9603|
|200-day moving average||$48.753|
|Wall St. target price||$63.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.038|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy NeoGenomics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
NeoGenomics price performance over time
|1 week (2021-04-30)||-2.13%|
|1 month (2021-04-08)||0.16%|
|3 months (2021-02-08)||-14.44%|
|6 months (2020-11-06)||17.92%|
|1 year (2020-05-08)||70.63%|
|2 years (2019-05-08)||115.49%|
|3 years (2018-05-08)||344.78%|
|5 years (2016-05-06)||491.21%|
Is NeoGenomics under- or over-valued?
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's P/E ratio
NeoGenomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1347x. In other words, NeoGenomics shares trade at around 1347x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NeoGenomics's PEG ratio
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$23.8 million.
The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$444.4 million|
|Gross profit TTM||USD$186.4 million|
|Return on assets TTM||-0.88%|
|Return on equity TTM||0.69%|
|Market capitalisation||USD$6.2 billion|
TTM: trailing 12 months
How to short and sell NeoGenomics shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "NEO.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 6.4 million NeoGenomics shares held short by investors – that's known as NeoGenomics's "short interest". This figure is 11.9% up from 5.7 million last month.
There are a few different ways that this level of interest in shorting NeoGenomics shares can be evaluated.
NeoGenomics's "short interest ratio" (SIR)
NeoGenomics's "short interest ratio" (SIR) is the quantity of NeoGenomics shares currently shorted divided by the average quantity of NeoGenomics shares traded daily (recently around 1.1 million). NeoGenomics's SIR currently stands at 5.64. In other words for every 100,000 NeoGenomics shares traded daily on the market, roughly 5640 shares are currently held short.
However NeoGenomics's short interest can also be evaluated against the total number of NeoGenomics shares, or, against the total number of tradable NeoGenomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeoGenomics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NeoGenomics shares in existence, roughly 50 shares are currently held short) or 0.0743% of the tradable shares (for every 100,000 tradable NeoGenomics shares, roughly 74 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeoGenomics.
Find out more about how you can short NeoGenomics stock.
NeoGenomics share dividends
We're not expecting NeoGenomics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have NeoGenomics's shares ever split?
NeoGenomics's shares were split on a 1:100 basis on 15 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
NeoGenomics share price volatility
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $25.19 up to $61.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.6845. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Frequently asked questions
More guides on Finder
How to buy Bragg Gaming Group stock in Canada
Steps to owning and managing Bragg Gaming Group Inc. (BRAG) stocks, with 24-hour and historical pricing before you buy.
How to buy Waterloo Brewing stock in Canada
Steps to owning and managing Waterloo Brewing (WBR) stocks, with 24-hour and historical pricing before you buy.
How to buy PyroGenesis Canada stock in Canada
Steps to owning and managing PyroGenesis Canada (PYR) stock, with 24-hour and historical pricing before you buy.
How to buy GoGold Resources stock in Canada
Steps to owning and managing GoGold Resources (GGD), with 24-hour and historical pricing before you buy.
How to buy Bio-Rad Laboratories stock in Canada
Steps to owning and managing BIO, with 24-hour and historical pricing before you buy.
How to buy Ares Management Corporation stock in Canada
Steps to owning and managing ARES, with 24-hour and historical pricing before you buy.
How to buy Brookfield Infrastructure Partners L-P stock in Canada
Steps to owning and managing BIP, with 24-hour and historical pricing before you buy.
How to buy Logitech International S-A stock in Canada
Steps to owning and managing LOGI, with 24-hour and historical pricing before you buy.
How to buy PerkinElmer stock in Canada
Steps to owning and managing PKI, with 24-hour and historical pricing before you buy.
How to buy Ubiquiti stock in Canada
Steps to owning and managing UI, with 24-hour and historical pricing before you buy.